UB Paderborn / Katalog / Suche / in CDI

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

The Lancet (British edition), 2015-06, Vol.385 (9987), p.2606-2615

2015

Volltextzugriff (PDF)

Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption

Advanced drug delivery reviews, 2008-03, Vol.60 (6), p.717-733

2008

Volltextzugriff (PDF)

A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults

Journal of acquired immune deficiency syndromes (1999), 2017-02, Vol.74 (2), p.193-200

2017

Volltextzugriff (PDF)

Pharmacokinetics of Tenofovir Alafenamide When Coadministered With Other HIV Antiretrovirals

Journal of acquired immune deficiency syndromes (1999), 2018-08, Vol.78 (4), p.465-472

2018

Volltextzugriff (PDF)

Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study

Journal of acquired immune deficiency syndromes (1999), 2016-04, Vol.71 (5), p.530-537

2016

Volltextzugriff (PDF)

Pharmacokinetics and Safety of Tenofovir Alafenamide in HIV-Uninfected Subjects with Severe Renal Impairment

Antimicrobial agents and chemotherapy, 2016-09, Vol.60 (9), p.5135-5140

2016

Volltextzugriff (PDF)

An In Vitro and In Vivo Evaluation of the Effect of Relacorilant on the Activity of Cytochrome P450 Drug Metabolizing Enzymes

Journal of clinical pharmacology, 2021-02, Vol.61 (2), p.244-253

2021

Volltextzugriff (PDF)

Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors

Clinical cancer research, 2022-08, Vol.28 (15), p.3214-3224

2022

Volltextzugriff (PDF)

Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study

Journal of clinical oncology, 2023-10, Vol.41 (30), p.4779-4789

2023

Volltextzugriff (PDF)

ITC Commentary on Metformin Clinical Drug–Drug Interaction Study Design That Enables an Efficacy‐ and Safety‐Based Dose Adjustment Decision

Clinical pharmacology and therapeutics, 2018-11, Vol.104 (5), p.781-784

2018

Volltextzugriff (PDF)

Relacorilant, a Selective Glucocorticoid Receptor Modulator in Development for the Treatment of Patients With Cushing Syndrome, Does Not Cause Prolongation of the Cardiac QT Interval

Endocrine practice, 2024-01, Vol.30 (1), p.11-18

2024

Volltextzugriff (PDF)

Drug Interactions with Cobicistat- or Ritonavir-Boosted Elvitegravir

AIDS reviews, 2016-04, Vol.18 (2), p.101

2016

Volltextzugriff (PDF)

Gab3, a New DOS/Gab Family Member, Facilitates Macrophage Differentiation

Molecular and Cellular Biology, 2002-01, Vol.22 (1), p.231-244

2002

Volltextzugriff (PDF)

Population Pharmacokinetics of Boosted-Elvitegravir in HIV-Infected Patients

Journal of clinical pharmacology, 2016-06, Vol.56 (6), p.723-732

2016

Volltextzugriff (PDF)

Gab3-Deficient Mice Exhibit Normal Development and Hematopoiesis and Are Immunocompetent

Molecular and Cellular Biology, 2003-04, Vol.23 (7), p.2415-2424

2003

Volltextzugriff (PDF)

Pharmacokinetics of Co-Formulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate After Switch From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Healthy Subjects

Journal of acquired immune deficiency syndromes (1999), 2016-07, Vol.72 (3), p.281-288

2016

Volltextzugriff (PDF)

Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial

AIDS research and therapy, 2014-12, Vol.11 (1), p.39-39

2014

Volltextzugriff (PDF)

Pharmacokinetics and Safety of Boosted Elvitegravir in Subjects with Hepatic Impairment

Antimicrobial agents and chemotherapy, 2014-05, Vol.58 (5), p.2564-2569

2014

Volltextzugriff (PDF)

Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatin

Journal of clinical pharmacology, 2014-06, Vol.54 (6), p.649-656

2014

Volltextzugriff (PDF)

Effect of food on rilpivirine/emtricitabine/tenofovir disoproxil fumarate, an antiretroviral single-tablet regimen for the treatment of HIV infection

Journal of clinical pharmacology, 2014-04, Vol.54 (4), p.378-385

2014

Volltextzugriff (PDF)

The pharmacokinetic and pharmacodynamic interactions between buprenorphine/naloxone and elvitegravir/cobicistat in subjects receiving chronic buprenorphine/naloxone treatment

Journal of acquired immune deficiency syndromes (1999), 2013-08, Vol.63 (4), p.480-484

2013

Volltextzugriff (PDF)

Lack of clinically important PK interaction between coformulated ledipasvir/sofosbuvir and rilpivirine/emtricitabine/tenofovir alafenamide

Pharmacology research & perspectives, 2017-10, Vol.5 (5), p.n/a

2017

Volltextzugriff (PDF)

SAT-224 Pharmacokinetics of the selective glucocorticoid receptor modulator miricorilant in healthy volunteers and patients with presumed metabolic dysfunction-associated steatohepatitis (MASH)

Journal of hepatology, 2024-06, Vol.80, p.S613-S614

2024

Volltextzugriff (PDF)

The intron 5/6 promoter region of the ship1 gene regulates expression in stem/progenitor cells of the mouse embryo

Developmental biology, 2005-07, Vol.283 (2), p.503-521

2005

Volltextzugriff (PDF)

Human lead exposure in a late 19th century mental asylum population

The Science of the total environment, 2007, Vol.372 (2), p.463-473

2007

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption

A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults

Pharmacokinetics of Tenofovir Alafenamide When Coadministered With Other HIV Antiretrovirals

Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study

Pharmacokinetics and Safety of Tenofovir Alafenamide in HIV-Uninfected Subjects with Severe Renal Impairment

An In Vitro and In Vivo Evaluation of the Effect of Relacorilant on the Activity of Cytochrome P450 Drug Metabolizing Enzymes

Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors

Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study

ITC Commentary on Metformin Clinical Drug–Drug Interaction Study Design That Enables an Efficacy‐ and Safety‐Based Dose Adjustment Decision

Relacorilant, a Selective Glucocorticoid Receptor Modulator in Development for the Treatment of Patients With Cushing Syndrome, Does Not Cause Prolongation of the Cardiac QT Interval

Drug Interactions with Cobicistat- or Ritonavir-Boosted Elvitegravir

Gab3, a New DOS/Gab Family Member, Facilitates Macrophage Differentiation

Population Pharmacokinetics of Boosted-Elvitegravir in HIV-Infected Patients

Gab3-Deficient Mice Exhibit Normal Development and Hematopoiesis and Are Immunocompetent

Pharmacokinetics of Co-Formulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate After Switch From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Healthy Subjects

Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial

Pharmacokinetics and Safety of Boosted Elvitegravir in Subjects with Hepatic Impairment

Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatin

Effect of food on rilpivirine/emtricitabine/tenofovir disoproxil fumarate, an antiretroviral single-tablet regimen for the treatment of HIV infection

The pharmacokinetic and pharmacodynamic interactions between buprenorphine/naloxone and elvitegravir/cobicistat in subjects receiving chronic buprenorphine/naloxone treatment

Lack of clinically important PK interaction between coformulated ledipasvir/sofosbuvir and rilpivirine/emtricitabine/tenofovir alafenamide

SAT-224 Pharmacokinetics of the selective glucocorticoid receptor modulator miricorilant in healthy volunteers and patients with presumed metabolic dysfunction-associated steatohepatitis (MASH)

The intron 5/6 promoter region of the ship1 gene regulates expression in stem/progenitor cells of the mouse embryo

Human lead exposure in a late 19th century mental asylum population

Suchergebnisse filtern